U.S. breast localization market to reach $878M by 2020

The U.S. breast localization market will reach $878 million by 2020, with a...Read more on AuntMinnie.comRelated Reading: Breast cancer diagnostic devices sector set for growth 3D breast tomosynthesis to overtake 2D mammo by 2019 Global breast imaging market to reach $4B by 2019 Breast cancer therapy market primed for growth Breast imaging market to hit $3B in 2019
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Cancer therapy decisions are often made according to the histopathological-molecular profile of tumor tissue obtained from surgery or biopsy. It has been shown that tumor profiles change with time and treatment, and that tumor tissue is heterogeneous. Thus, other approaches that are easily accessible and less invasive than surgery or biopsy to monitor responses to treatment and predict relapses are urgently needed. In the last few years, the term “liquid biopsies” has been introduced to represent multifunctional circulating biomarkers in the peripheral blood and other physiological fluids of patients with cance...
Source: Oncology - Category: Cancer & Oncology Source Type: research
Abstract Cancer therapy decisions are often made according to the histopathological-molecular profile of tumor tissue obtained from surgery or biopsy. It has been shown that tumor profiles change with time and treatment, and that tumor tissue is heterogeneous. Thus, other approaches that are easily accessible and less invasive than surgery or biopsy to monitor responses to treatment and predict relapses are urgently needed. In the last few years, the term "liquid biopsies" has been introduced to represent multifunctional circulating biomarkers in the peripheral blood and other physiological fluids of pat...
Source: Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Source Type: research
In conclusion, the findings of the present study demonstrated that high‑dose MTX enhanced anticancer activity in α‑TOS‑treated TNBC, while low‑dose MTX reduced anticancer activity in α‑TOS‑treated TNBC. PMID: 30628707 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
(Louisiana State University Health Sciences Center) Research led by Suresh Alahari, PhD, the Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health New Orleans School of Medicine, has found a new role for a protein discovered by his lab in preventing the growth and spread of breast cancer.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Abstract INTRODUCTION: Cancer, in particular breast cancer, is one of the leading causes of death among women. Good nutritional status contributes to the efficacy of treatment and recovery, and nutritional interventions can minimize the adverse effects of cancer therapy. AIM: The aim of this study was to describe the potential role of dietary counseling in breast cancer patients. The impact of nutritional advice on the nutritional status of patients, the use of dietary supplements, and the knowledge of phytoestrogens were assessed. MATERIALS AND METHODS: The study was conducted between April and July 201...
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Tags: Nutr Cancer Source Type: research
In this study, we investigated whether and how SSRIs induce the death of human breast cancer MCF-7 cells. Of the antidepressants tested in this study (amitriptyline, bupropion, fluoxetine, paroxetine, and tianeptine), paroxetine most reduced the viability of MCF-7 cells in a time-and dose-dependent manner. The exposure of MCF-7 cells to paroxetine resulted in mitochondrion-mediated apoptosis, which is assessed by increase in the number of cells with sub-G1 DNA content, caspase-8/9 activation, poly (ADP-ribose) polymerase cleavage, and Bax/Bcl-2 ratio and a reduction in the mitochondrial membrane potential. Paroxetine incre...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: April 2019Source: Materials Science and Engineering: C, Volume 97Author(s): Sajed Amjadi, Hamed Hamishehkar, Marjan GhorbaniAbstractBetanin (BET) can reduce the side effects of potent anticancer drugs e.g. doxorubicin (DOX) on the normal tissues in co-administration with them because of the synergistic therapeutic effect and consequently the reduced required amount of anticancer agents. Despite interest in the use of BET, incomplete oral absorption and low stability of BET limit its application. Thus, in this study to overcome the restrictions of BET and providing the synergistic effect of DOX@BET, we des...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
CONCLUSION: Closer follow-ups, tailor-made information about the proven benefits of ET, and keeping a normal body mass index (BMI) may improve adherence to ET in postmenopausal women with breast cancer. PMID: 30641300 [PubMed - as supplied by publisher]
Source: Breast - Category: Cancer & Oncology Authors: Tags: Breast Source Type: research
Authors: You SH, Chae BJ, Eom YH, Yoo TK, Kim YS, Kim JS, Park WC Abstract Purpose: Triple-positive breast cancer is defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) positivity. Several systemic breast cancer therapies target hormonal and HER2 responsiveness. We compared clinical outcomes of triple-positive disease with those of HER2-enriched and luminal HER2-negative disease and investigated the clinical efficacy of anti-HER2 therapy for triple-positive disease. Methods: We retrospectively compared overall and recurrence-free survival among cases included...
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
Abstract Copper plays an important role in tumor growth and metastasis. Copper chelation has been confirmed to be an effective strategy for breast cancer therapy through antiangiogenesis. In this work, a copper chelating coil-comb block copolymer RGD-PEG-b-PGA-g-(TETA-DTC-PHis) (RPTDH) was synthesized and used to prepare nanoparticles for loading resiquimod (R848), a TLR7 and TLR8 agonist, thus to combine antiangiogenesis and immune activation to treat breast cancer. RPTDH has strong copper-chelating ability and could self-assemble to form spherical nanoparticles with significant pH-sensitivity. R848 was efficient...
Source: Biomaterials - Category: Materials Science Authors: Tags: Biomaterials Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Radiology